Literature DB >> 24862179

Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.

Marina Kremyanskaya1, John Mascarenhas, Raajit Rampal, Ronald Hoffman.   

Abstract

Entities:  

Keywords:  acute myeloid leukaemia; clinical haematology; haematological malignancies; myelofibrosis

Mesh：

Substances：

Year:  2014        PMID： 24862179     DOI： 10.1111/bjh.12948

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Authors:  Kiran Naqvi; Naval Daver; Naveen Pemmaraju; Prithviraj Bose; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2016-08-05

3.  How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Authors:  G Barosi; R P Gale
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

Review 4.  Myelofibrosis: to transplant or not to transplant?

Authors:  Rebecca Devlin; Vikas Gupta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.

Authors:  Sophia S Lee; Srdan Verstovsek; Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-06-29

Review 6.  Modern management of splenomegaly in patients with myelofibrosis.

Authors:  Douglas Tremblay; Myron Schwartz; Richard Bakst; Rahul Patel; Thomas Schiano; Marina Kremyanskaya; Ronald Hoffman; John Mascarenhas
Journal:  Ann Hematol       Date:  2020-05-17       Impact factor: 3.673

7.  Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Authors:  Daria V Babushok; Ernest J Nelson; Jennifer J D Morrissette; Shivam Joshi; Matthew B Palmer; Dale Frank; Carolyn L Cambor; Elizabeth O Hexner
Journal:  Leuk Lymphoma       Date:  2018-09-19

Review 8.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

Review 9.  Polycythemia vera treatment algorithm 2018.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-10       Impact factor: 11.037

10.  Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Expert Rev Hematol       Date:  2020-10-19       Impact factor: 2.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.